Skip to main content
| Hans-Günter Meyer-Thompson | Verschiedenes

Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A.

Pharmacoepidemiol Drug Saf. 2018 Sep 25. doi: 10.1002/pds.4635. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30251424